• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纳米放射性药物作为治疗剂。

Nano-radiopharmaceuticals as therapeutic agents.

作者信息

Dixit Tanu, Dave Nayomi, Basu Kausani, Sonawane Pranav, Gawas Trutuja, Ravindran Selvan

机构信息

Symbiosis School of Biological Sciences, Faculty of Medical and Health Sciences, Symbiosis International (Deemed University), Lavale, Pune, India.

出版信息

Front Med (Lausanne). 2024 Mar 15;11:1355058. doi: 10.3389/fmed.2024.1355058. eCollection 2024.

DOI:10.3389/fmed.2024.1355058
PMID:38560384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10978739/
Abstract

In recent years, there has been an increased interest in exploring the potential synergy between nanotechnology and nuclear medicine. The application of radioactive isotopes, commonly referred to as radiopharmaceuticals, is recognized in nuclear medicine for diagnosing and treating various diseases. Unlike conventional pharmaceutical agents, radiopharmaceuticals are designed to work without any pharmacological impact on the body. Nevertheless, the radiation dosage employed in radiopharmaceuticals is often sufficiently high to elicit adverse effects associated with radiation exposure. Exploiting their capacity for selective accumulation on specific organ targets, radiopharmaceuticals have utility in treating diverse disorders. The incorporation of nanosystems may additionally augment the targeting capability of radiopharmaceuticals, leveraging their distinct pharmacokinetic characteristics. Conversely, radionuclides could be used in research to assess nanosystems pharmacologically. However, more investigation is needed to verify the safety and effectiveness of radiopharmaceutical applications mediated by nanosystems. The use of nano-radiopharmaceuticals as therapeutic agents to treat various illnesses and disorders is majorly covered in this review. The targeted approach to cancer therapy and various types of nanotools for nano-radiopharmaceutical delivery, is also covered in this article.

摘要

近年来,人们对探索纳米技术与核医学之间潜在的协同作用越来越感兴趣。放射性同位素(通常称为放射性药物)的应用在核医学中被认可用于诊断和治疗各种疾病。与传统药物不同,放射性药物的设计目的是在不对身体产生任何药理作用的情况下发挥作用。然而,放射性药物中使用的辐射剂量通常足够高,会引发与辐射暴露相关的不良反应。利用其在特定器官靶点上选择性积累的能力,放射性药物可用于治疗多种疾病。纳米系统的加入可能会进一步增强放射性药物的靶向能力,利用其独特的药代动力学特性。相反,放射性核素可用于研究中对纳米系统进行药理学评估。然而,需要更多的研究来验证纳米系统介导的放射性药物应用的安全性和有效性。本综述主要涵盖了使用纳米放射性药物作为治疗剂来治疗各种疾病和病症。本文还介绍了癌症治疗的靶向方法以及用于纳米放射性药物递送的各种类型的纳米工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d02c/10978739/2fba7a84a011/fmed-11-1355058-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d02c/10978739/04dc7620fa94/fmed-11-1355058-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d02c/10978739/2fba7a84a011/fmed-11-1355058-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d02c/10978739/04dc7620fa94/fmed-11-1355058-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d02c/10978739/2fba7a84a011/fmed-11-1355058-g002.jpg

相似文献

1
Nano-radiopharmaceuticals as therapeutic agents.纳米放射性药物作为治疗剂。
Front Med (Lausanne). 2024 Mar 15;11:1355058. doi: 10.3389/fmed.2024.1355058. eCollection 2024.
2
Nanotechnology and radiopharmaceuticals: diagnostic and therapeutic approaches.纳米技术与放射性药物:诊断与治疗方法。
Curr Drug Deliv. 2010 Apr;7(2):168-74. doi: 10.2174/156720110791011837.
3
Nanoradiopharmaceuticals: is that the future for nuclear medicine?纳米放射性药物:这会是核医学的未来吗?
Curr Radiopharm. 2011 Apr;4(2):140-3. doi: 10.2174/1874471011104020140.
4
Transforming Nuclear Medicine with Nanoradiopharmaceuticals.用纳米放射性药物变革核医学。
ACS Nano. 2022 Apr 26;16(4):5036-5061. doi: 10.1021/acsnano.1c10550. Epub 2022 Mar 16.
5
Radiopharmaceutical enhancement by drug delivery systems: A review.放射性药物给药系统的增强作用:综述。
J Control Release. 2018 Oct 10;287:177-193. doi: 10.1016/j.jconrel.2018.08.008. Epub 2018 Aug 4.
6
Nanoparticulate formulations of radiopharmaceuticals: Strategy to improve targeting and biodistribution properties.放射性药物的纳米颗粒制剂:改善靶向性和生物分布特性的策略。
J Labelled Comp Radiopharm. 2020 Mar 27. doi: 10.1002/jlcr.3839.
7
Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts.用于癌症诊断与治疗的放射性标记纳米材料:原理与概念
Cancer Nanotechnol. 2023;14(1):15. doi: 10.1186/s12645-023-00165-y. Epub 2023 Feb 27.
8
Therapeutic radiopharmaceuticals.治疗性放射性药物
Curr Pharm Des. 2000 Jul;6(11):1085-121. doi: 10.2174/1381612003399833.
9
Bifunctional chelators in the design and application of radiopharmaceuticals for oncological diseases.双功能螯合剂在肿瘤疾病放射性药物设计与应用中的作用。
Curr Med Chem. 2012;19(17):2667-88. doi: 10.2174/092986712800609751.
10
Development of the occupational exposure during the production and application of radiopharmaceuticals in Germany.德国放射性药物生产和应用过程中职业照射的发展。
J Radiol Prot. 2024 Feb 6;44(1). doi: 10.1088/1361-6498/ad1fdd.

引用本文的文献

1
Radiolabeled Nanogels: From Multimodality Imaging to Combination Therapy of Cancer.放射性标记的纳米凝胶:从多模态成像到癌症联合治疗
Small Sci. 2025 Jun 19;5(8):2400298. doi: 10.1002/smsc.202400298. eCollection 2025 Aug.
2
Nanocarriers for cutting-edge cancer immunotherapies.用于前沿癌症免疫疗法的纳米载体。
J Transl Med. 2025 Apr 16;23(1):447. doi: 10.1186/s12967-025-06435-0.
3
Nano-Radiopharmaceuticals in Colon Cancer: Current Applications, Challenges, and Future Directions.纳米放射性药物在结肠癌中的应用:当前应用、挑战与未来方向

本文引用的文献

1
PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.PSMA 靶向放射性药物在前列腺癌中的应用:现有数据和新试验。
Oncologist. 2023 May 8;28(5):392-401. doi: 10.1093/oncolo/oyac279.
2
Targeted thorium-227 conjugates as treatment options in oncology.靶向钍-227偶联物作为肿瘤学中的治疗选择。
Front Med (Lausanne). 2023 Jan 9;9:1071086. doi: 10.3389/fmed.2022.1071086. eCollection 2022.
3
Radiopharmaceutical Encapsulated Liposomes as a Novel Radiotracer Im - aging and Drug Delivery Protocol.放射性药物包裹脂质体作为一种新型放射性示踪剂成像和药物输送方案。
Pharmaceuticals (Basel). 2025 Feb 14;18(2):257. doi: 10.3390/ph18020257.
Curr Radiopharm. 2023;16(2):133-139. doi: 10.2174/1874471016666221202094628.
4
Holmium-166 Radioembolization: Current Status and Future Prospective.钬 166 放射性栓塞治疗:现状与未来展望。
Cardiovasc Intervent Radiol. 2022 Nov;45(11):1634-1645. doi: 10.1007/s00270-022-03187-y. Epub 2022 Jun 21.
5
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective.用于解码癌症微生物组相互作用的振动光谱学:当前证据和未来展望。
Semin Cancer Biol. 2022 Nov;86(Pt 3):743-752. doi: 10.1016/j.semcancer.2021.07.004. Epub 2021 Jul 14.
6
Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study.钍标记的抗CD22抗体(BAY 1862864)用于复发/难治性CD22阳性非霍奇金淋巴瘤:一项首次人体I期研究。
Cancer Biother Radiopharm. 2021 Oct;36(8):672-681. doi: 10.1089/cbr.2020.4653. Epub 2021 Apr 21.
7
Radiopharmaceutical therapy in cancer: clinical advances and challenges.放射性药物治疗癌症:临床进展与挑战。
Nat Rev Drug Discov. 2020 Sep;19(9):589-608. doi: 10.1038/s41573-020-0073-9. Epub 2020 Jul 29.
8
Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.聚合物纳米载体递送 binimetinib(MEK162)联合放疗和替莫唑胺治疗脑胶质瘤的临床前评价。
J Neurooncol. 2020 Jan;146(2):239-246. doi: 10.1007/s11060-019-03365-y. Epub 2019 Dec 24.
9
Ultrafast Synthesizing Bismuth Mesoporous Nanolitchi Radiosensitizer Loading High Dose DOX for CT-Guided Enhanced Chemoradiotherapy.超快合成载高剂量 DOX 的铋介孔纳米利奇 Radiosensitizer,用于 CT 引导的增强放化疗。
ACS Appl Mater Interfaces. 2019 Nov 20;11(46):42932-42942. doi: 10.1021/acsami.9b13647. Epub 2019 Oct 17.
10
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.间皮素靶向钍-227偶联物(MSLN-TTC):间皮素阳性癌症新型靶向α疗法的临床前评估
Clin Cancer Res. 2019 Aug 1;25(15):4723-4734. doi: 10.1158/1078-0432.CCR-18-3476. Epub 2019 May 7.